CINECA IRIS Institutional Research Information System

LORUSSO, LOREDANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.549
EU - Europa 1.406
AS - Asia 1.342
SA - Sud America 210
AF - Africa 83
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.598
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.494
SG - Singapore 434
IT - Italia 421
CN - Cina 395
DE - Germania 337
HK - Hong Kong 182
SE - Svezia 171
BR - Brasile 164
GB - Regno Unito 115
VN - Vietnam 105
AT - Austria 78
BG - Bulgaria 68
FR - Francia 53
RU - Federazione Russa 43
IN - India 42
JP - Giappone 40
FI - Finlandia 36
CA - Canada 35
CI - Costa d'Avorio 26
TR - Turchia 25
SN - Senegal 21
KR - Corea 20
MA - Marocco 20
NL - Olanda 20
BD - Bangladesh 15
IQ - Iraq 15
AR - Argentina 13
MX - Messico 12
PL - Polonia 12
PH - Filippine 11
UZ - Uzbekistan 10
UA - Ucraina 9
CH - Svizzera 7
CL - Cile 7
ZA - Sudafrica 7
CO - Colombia 6
ID - Indonesia 6
SA - Arabia Saudita 6
VE - Venezuela 6
AU - Australia 5
CZ - Repubblica Ceca 5
EC - Ecuador 5
ES - Italia 5
LB - Libano 5
LT - Lituania 5
PK - Pakistan 5
IR - Iran 4
RO - Romania 4
UY - Uruguay 4
EG - Egitto 3
IL - Israele 3
KZ - Kazakistan 3
MY - Malesia 3
PT - Portogallo 3
AL - Albania 2
EE - Estonia 2
IE - Irlanda 2
JO - Giordania 2
NP - Nepal 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
A1 - Anonimo 1
AZ - Azerbaigian 1
BB - Barbados 1
BE - Belgio 1
BH - Bahrain 1
BO - Bolivia 1
CR - Costa Rica 1
DK - Danimarca 1
ET - Etiopia 1
GA - Gabon 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
JM - Giamaica 1
KG - Kirghizistan 1
KI - Kiribati 1
LY - Libia 1
MM - Myanmar 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PE - Perù 1
PS - Palestinian Territory 1
QA - Qatar 1
SR - Suriname 1
SY - Repubblica araba siriana 1
Totale 5.598
Salva come PNG Salva come JPEG
Città #
Ashburn 329
Singapore 249
Dallas 239
Hong Kong 180
Milan 177
Chandler 174
San Jose 172
Fairfield 149
Santa Clara 131
Woodbridge 130
Seattle 86
Houston 85
New York 80
Shanghai 76
Vienna 73
Sofia 67
Beijing 59
Los Angeles 59
Cambridge 54
Wilmington 54
Ann Arbor 52
Munich 50
London 39
Hefei 37
Princeton 36
Florence 35
Boardman 33
Ho Chi Minh City 31
Rome 31
Tokyo 31
Council Bluffs 30
Frankfurt am Main 27
Lauterbourg 27
Abidjan 26
Lawrence 25
Dearborn 22
Dakar 21
Bremen 20
Medford 20
Seoul 19
Hanoi 18
Pisa 18
São Paulo 18
Turku 17
Redondo Beach 16
Ottawa 13
Casablanca 12
Dong Ket 12
Redwood City 12
Denver 11
Phoenix 11
San Diego 11
Serra 11
Atlanta 10
Des Moines 10
Helsinki 10
Nanjing 10
Warsaw 10
Baghdad 9
Fuzhou 9
Nuremberg 9
Orem 9
Tashkent 9
Washington 9
Buffalo 8
Istanbul 8
Montreal 8
Ogden 8
Toronto 8
Amsterdam 7
Brooklyn 7
Chicago 7
Lancaster 7
Quanzhou 7
Salt Lake City 7
Belo Horizonte 6
Izmir 6
Nanchang 6
Redmond 6
Scandicci 6
Shenyang 6
Stockholm 6
Ankara 5
Boston 5
Chiesina Uzzanese 5
Cleveland 5
Johannesburg 5
Manila 5
San Francisco 5
Tianjin 5
Bern 4
Brno 4
Chengdu 4
Delhi 4
Dhaka 4
Düsseldorf 4
Guangzhou 4
Kyiv 4
Mumbai 4
Paris 4
Totale 3.723
Salva come PNG Salva come JPEG
Nome #
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 244
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 234
Targeted Therapy in Thyroid Cancer: State of the Art 224
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 217
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 214
Thyroid autoimmunity, thyroglobulin autoantibodies and thyroid cancer prognosis 211
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 209
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 205
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 204
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 203
Influence of Lymphocytic Thyroiditis at Histology and Serum Thyroglobulin Autoantibodies on the Course of Papillary Thyroid Carcinoma 201
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 196
Il carcinoma tiroideo: nuove prospettive terapeutiche. 191
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer 190
Less than 2% of the low- and intermediate-risk differentiated thyroid cancers show distant metastases at post-ablation whole-body scan 179
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 177
Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features 171
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 170
Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates 170
Systemic treatment of advanced, metastatic, medullary thyroid carcinoma 163
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 162
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 161
Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST 161
Significance of Thyroglobulin Autoantibodies in Patients With Thyroid Cancer Treated With Lenvatinib 155
Carcinoma tiroideo e gravidanza. 144
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 136
Ret mutated C-cells proliferate more rapidly than non-mutated neoplastic cells 129
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center 127
Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer 125
Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response 119
Hand-foot syndrome in sorafenib and lenvatinib treatment for advanced thyroid cancer 97
null 70
null 54
Risultati dello studio di fase III, randomizzato, controllato, in doppio cieco, Sorafenib vs Placebo nel trattamento del carcinoma differenziato della tiroide (CDT) localmente avanzato o metastatico, refrattario al 131I, in progressione. 39
Molecular Profile of Advanced Radioiodine-refractory Thyroid Cancer and Response to Lenvatinib Treatment 19
Determinants of Health-Related Quality of Life in Differentiated and Poorly Differentiated Thyroid Cancer Patients With Structural Incomplete Response: A Multicenter Cross-Sectional Study 13
Follicular thyroid cancer in lenvatinib therapy complicated by tracheoesophageal fistula treated with pharyngo-laryngo-esophagectomy and definitive tracheostomy 10
Totale 5.694
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.751
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.751
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202133 0 0 0 0 0 0 0 0 0 0 0 33
2021/2022318 19 6 2 13 62 47 10 16 25 19 22 77
2022/2023653 73 104 53 65 63 76 6 36 105 14 48 10
2023/2024519 60 70 78 47 67 87 19 8 6 7 22 48
2024/20251.198 9 42 13 64 121 106 108 65 113 144 138 275
2025/20261.767 162 266 170 183 183 125 246 66 128 159 53 26
Totale 5.694